Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 21, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically concerning the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On November 16, 2007, there was an increase in the notional allocation of Ordinary Share ADRs at a price of $48.95 per ADR share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing reports a transaction involving Dr. R G Greig regarding the US Retirement Savings Plan.
- The transaction involved an increase in notional allocation of Ordinary Share ADRs on November 16, 2007.
- The price per ADR share for this transaction was $48.95.
- This document does not contain financial results or operational updates for the company.